SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Anthony Tran who wrote (5)6/24/1996 6:49:00 PM
From: DOUBLE   of 496
 
Guilford's overall stance within the pharmaceutical industry is more than favorable. While Guilford's Gliadeld biodegradable wafer was only approved for surgery as an adjunct for the treatment of recurrent glioblastoma multiforme (GBM), it's approved labeling indication allows the implant to be used on roughly three quarters of the operable brain cancers. Following Gliadel's final approval this summer, the drug will generate revenues in excess of $100 million dollars by the year 2000. The recent arrangement between Rhone Poulenc Rorer and Guilford already provides Guilford with $7.5 million in cash, $7.5 million in equity, along with an established $7.5 million line of credit. Guilford will also receive $60 million in milestone payments, in addition to royalties on all sales of Gliadel. This deal alone provides Guilford with a foundation that is limitless!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News